Notice of Class Action Lawsuit Against Atara Biotherapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy ATRA?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the regulatory prospects of its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to choose legal counsel carefully, as Rosen Law Firm emphasizes selecting attorneys with a proven track record in securities class actions to avoid partnering with firms that merely act as intermediaries, ensuring effective protection of their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.240
Low
18.00
Averages
21.50
High
25.00
Current: 5.240
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Regulatory Scrutiny Risks: The lawsuit alleges that Atara misled investors about the regulatory prospects of its lead drug candidate, tabelecleucel, particularly due to manufacturing issues and deficiencies in the ALLELE study, making FDA approval unlikely and exposing the company to heightened regulatory scrutiny.
- Stock Price Plunge Impact: Following a press release on January 12, 2026, announcing that the FDA issued a Complete Response Letter regarding tabelecleucel, Atara's stock price plummeted by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, indicating the importance of corporate governance and shareholder rights in the wake of potential mismanagement issues.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The complaint claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for tabelecleucel, thereby increasing regulatory scrutiny and jeopardizing ongoing clinical trials.
- Financial Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, rendering the company's public statements materially false or misleading during the relevant period.
- Investor Action: Affected investors have until May 22, 2026, to request lead plaintiff status, with the law firm representing investors on a contingency fee basis, only charging if successful.
See More
Faruqi & Faruqi Encourages Atara Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating that the company may face legal risks, prompting investors to be vigilant about their investment safety.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, and failure to act promptly may result in the loss of rights in the lawsuit, impacting potential compensation opportunities.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing multiple contact options, which demonstrates the firm's commitment to supporting investor rights and interests.
- Market Reaction Anticipation: As the legal investigation unfolds, the market may react negatively to Atara's stock price, necessitating investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notification: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during this period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation became known, negatively impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediary firms.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Regulatory Scrutiny Risks: The lawsuit alleges that Atara misled investors about the regulatory prospects of its lead drug candidate, tabelecleucel, particularly due to manufacturing issues and deficiencies in the ALLELE study, making FDA approval unlikely and exposing the company to heightened regulatory scrutiny.
- Stock Price Plunge Impact: Following a press release on January 12, 2026, announcing that the FDA issued a Complete Response Letter regarding tabelecleucel, Atara's stock price plummeted by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, indicating the importance of corporate governance and shareholder rights in the wake of potential mismanagement issues.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The complaint claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for tabelecleucel, thereby increasing regulatory scrutiny and jeopardizing ongoing clinical trials.
- Financial Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, rendering the company's public statements materially false or misleading during the relevant period.
- Investor Action: Affected investors have until May 22, 2026, to request lead plaintiff status, with the law firm representing investors on a contingency fee basis, only charging if successful.
See More
Faruqi & Faruqi Encourages Atara Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating that the company may face legal risks, prompting investors to be vigilant about their investment safety.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, and failure to act promptly may result in the loss of rights in the lawsuit, impacting potential compensation opportunities.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing multiple contact options, which demonstrates the firm's commitment to supporting investor rights and interests.
- Market Reaction Anticipation: As the legal investigation unfolds, the market may react negatively to Atara's stock price, necessitating investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notification: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during this period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation became known, negatively impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediary firms.
See More
